Guidance for Clinicians
As a result of the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and state health departments’ ongoing investigation of contamination at the New England Compounding Center’s (NECC) Framingham, Massachusetts facility, on October 4, the FDA advised providers to not use any NECC products.
The FDA has issued new guidance for providers to contact their patients for whom they administered an injectable product, including an ophthalmic drug that is injectable or used in conjunction with eye surgery, or a cardioplegic solution purchased from or produced by NECC after May 21, 2012.
- FDA Updates on Fungal Meningitis Outbreak
- FDA Questions and Answers on Fungal Meningitis Outbreak
- CDC Clinician Guidance on Fungal Meningitis Outbreak
- CDC Multistate Fungal Meningitis Outbreak Investigation
- NECC Press Release
Clinicians are also requested to report any suspected adverse events following use of these products to both FDA's MedWatch program at 1-800-332-1088 or www.fda.gov/medwatch and to the DPH Infectious Diseases Section at 860-509-7995.
Health care professionals may dial FDA’s Drug Information Line at 855-543-DRUG (3784) and press * to get the most recent information regarding the meningitis recall and speak directly to a pharmacist.
Guidance for Patients
Patients who are concerned that they may have received NECC products should contact their healthcare provider.